Laurus Labs Limited (BOM:540222)

Market Cap	281.19B
Revenue (ttm)	52.73B
Net Income (ttm)	2.00B
Shares Out	n/a
EPS (ttm)	3.70
PE Ratio	140.41
Forward PE	n/a
Dividend	0.80 (0.15%)
Ex-Dividend Date	Nov 6, 2024

Volume	40,056
Average Volume	173,222
Open	539.50
Previous Close	546.45
Day's Range	531.30 - 549.05
52-Week Range	372.20 - 646.25
Beta	n/a
RSI	35.69
Earnings Date	Apr 25, 2025

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational ser...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2005
• Employees: 6,007
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540222

Financial Performance

In 2023, Laurus Labs's revenue was 50.41 billion, a decrease of -16.55% compared to the previous year's 60.41 billion. Earnings were 1.61 billion, a decrease of -79.68%.